<DOC>
	<DOCNO>NCT00971893</DOCNO>
	<brief_summary>The present study design collect data real world experience use Medrol acute asthma Indian patient .</brief_summary>
	<brief_title>A Study To Assess The Safety And Effectiveness Of Medrol® In Acute Asthma In Indian Patients</brief_title>
	<detailed_description>Sequential enrollment</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<criteria>To eligible enrollment study , patient must prescribe oral Medrol® tablet ( 4mg 16 mg ) acute asthma per locally approve prescribing information . The prescription Medrol® separate decision include patient study . Medrol® tablet , prescribe patient physician accord his/her usual practice . The decision prescribe Medrol® tablet necessarily precede independent decision enroll patient study . Only patient prescribe Medrol® tablet evaluate potential eligibility study Only patient , ready willing sign inform consent , include study Subject contact telephone Based upon history physical exam emergency department ( ED ) Clinic , subject know suspected cause pulmonary symptom asthma , COPD , CHF , pneumonia , pulmonary embolism , angioedema Any contraindication Medrol tablet use . Contraindications Medrol use systemic fungal infection know hypersensitivity component</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2009</verification_date>
	<keyword>Acute Exacerbation Bronchial Asthma Acute Asthma</keyword>
</DOC>